Mavoglurant as a treatment for Parkinson’s disease
暂无分享,去创建一个
M. Pallàs | A. Camins | J. Folch | C. Auladell | A. Canudas | A. Lazarowski | M. L. de Lemos | C. Beas‐Zárate | Ignacio Pedrós | Dmitry Petrov
[1] R. Hauser,et al. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients , 2016, The International journal of neuroscience.
[2] P. L. McCormack. Rasagiline: A Review of Its Use in the Treatment of Idiopathic Parkinson’s Disease , 2014, CNS Drugs.
[3] P. Riederer,et al. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity , 2014, Journal of Neural Transmission.
[4] Y. Izumi,et al. Intracellular mGluR5 Can Mediate Synaptic Plasticity in the Hippocampus , 2014, The Journal of Neuroscience.
[5] A. Bruns,et al. Chronic Metabotropic Glutamate Receptor 5 Inhibition Corrects Local Alterations of Brain Activity and Improves Cognitive Performance in Fragile X Mice , 2014, Biological Psychiatry.
[6] S. Dutta,et al. Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets , 2014, British journal of clinical pharmacology.
[7] F. Gasparini,et al. Development of mavoglurant and its potential for the treatment of fragile X syndrome , 2014, Expert opinion on investigational drugs.
[8] M. Hechenberger,et al. Scaffold hopping approach towards various AFQ-056 analogs as potent metabotropic glutamate receptor 5 negative allosteric modulators. , 2013, Bioorganic & medicinal chemistry letters.
[9] F. Ciruela,et al. Targeting striatal metabotropic glutamate receptor type 5 in Parkinson's disease: bridging molecular studies and clinical trials. , 2013, CNS & neurological disorders drug targets.
[10] A. Destée,et al. AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study , 2013, Movement disorders : official journal of the Movement Disorder Society.
[11] E. Ansorena,et al. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems. , 2013, Maturitas.
[12] L. Grégoire,et al. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys , 2013, Neuropharmacology.
[13] J. Brotchie,et al. TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque , 2013, Neuropharmacology.
[14] K. Newell. Metabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs. , 2013, Future medicinal chemistry.
[15] A. Vortmeyer,et al. Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein , 2013, Neuron.
[16] A. Schapira,et al. Therapeutic prospects for Parkinson disease , 2013, Annals of neurology.
[17] Yi Jin,et al. Metabolism and Disposition of the Metabotropic Glutamate Receptor 5 Antagonist (mGluR5) Mavoglurant (AFQ056) in Healthy Subjects , 2013, Drug Metabolism and Disposition.
[18] J. Jordán,et al. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data. , 2013, Pharmacological research.
[19] A. Björklund,et al. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa‐induced dyskinesia , 2013, Movement disorders : official journal of the Movement Disorder Society.
[20] M. Naoi,et al. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms , 2013, Expert review of neurotherapeutics.
[21] P. Mazzoni,et al. The role of neuroplasticity in dopaminergic therapy for Parkinson disease , 2013, Nature Reviews Neurology.
[22] K. Emmitte. mGlu5 negative allosteric modulators: a patent review (2010 – 2012) , 2013, Expert opinion on therapeutic patents.
[23] S. Chaki,et al. mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants , 2013, Neuropharmacology.
[24] L. Grégoire,et al. MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates , 2013, Neuropharmacology.
[25] Ilse Gantois,et al. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice , 2013, Behavioural Brain Research.
[26] J. Brotchie,et al. Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials , 2013, Movement disorders : official journal of the Movement Disorder Society.
[27] J. Brotchie,et al. The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease , 2013, Pharmacological Reviews.
[28] S. Sudakov,et al. Role of Metabotropic Glutamate Receptors in the Mechanisms of Experimental Parkinsonism Development , 2012, Bulletin of Experimental Biology and Medicine.
[29] B. Elahi,et al. N-Methyl-D-Aspartate Antagonists in Levodopa Induced Dyskinesia: A Meta-Analysis , 2012, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[30] A. Lawrence,et al. The mGlu5 receptor antagonist MTEP attenuates opiate self-administration and cue-induced opiate-seeking behaviour in mice. , 2012, Drug and alcohol dependence.
[31] T. Müller. Drug therapy in patients with Parkinson’s disease , 2012, Translational Neurodegeneration.
[32] P. Conn,et al. Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease. , 2012, Neurodegenerative disease management.
[33] M. Cenci,et al. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease , 2012, Progress in Neurobiology.
[34] A. Schapira. Monoamine Oxidase B Inhibitors for the Treatment of Parkinson’s Disease , 2011, CNS drugs.
[35] C. Parsons,et al. Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on l-DOPA-induced dyskinesia , 2011, Journal of Neural Transmission.
[36] M. Lew. The Evidence for Disease Modification in Parkinson's Disease , 2011, The International journal of neuroscience.
[37] M. Mancuso,et al. Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues. , 2011, Current medicinal chemistry.
[38] T. Wichmann,et al. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. , 2011, Brain : a journal of neurology.
[39] L. Grégoire,et al. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications , 2011, Neurobiology of Aging.
[40] C. Ríos,et al. Medical Management of Parkinson’s Disease: Focus on Neuroprotection , 2011, Current neuropharmacology.
[41] J. Godau,et al. AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials , 2011, Movement disorders : official journal of the Movement Disorder Society.
[42] S. Wigal,et al. Pharmacokinetic evaluation of eltoprazine , 2011, Expert opinion on drug metabolism & toxicology.
[43] L. Grégoire,et al. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. , 2011, Parkinsonism & related disorders.
[44] Werner Poewe,et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes , 2011, The Lancet Neurology.
[45] V. Mutel,et al. mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents. , 2011, Current topics in medicinal chemistry.
[46] Jens Meiler,et al. Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential , 2011, Neuropharmacology.
[47] A. Brownell,et al. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease , 2010, Neuroscience Letters.
[48] M. Kowalska,et al. Neuroprotective potential of mGluR5 antagonist MTEP: effects on kainate-induced excitotoxicity in the rat hippocampus , 2010 .
[49] Qin Li,et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys , 2010, Neurobiology of Disease.
[50] V. Sossi,et al. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations. , 2010, Parkinsonism & related disorders.
[51] J. Brotchie,et al. Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2010, Journal of Pharmacology and Experimental Therapeutics.
[52] Charles D Blaha,et al. Acetylcholine–Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders , 2010, CNS neuroscience & therapeutics.
[53] K. Fuxe,et al. Adenosine–Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders , 2010, CNS neuroscience & therapeutics.
[54] L. Grégoire,et al. Effect of l‐Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys , 2010, Journal of neurochemistry.
[55] J. Obeso,et al. The pathophysiological basis of sensory disturbances in Parkinson's disease , 2010, Journal of the Neurological Sciences.
[56] Maurizio Memo,et al. Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole , 2010, BMC pharmacology.
[57] P. Conn,et al. Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.
[58] Werner Poewe,et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. , 2009, The New England journal of medicine.
[59] G. Arbuthnott,et al. Dealing with the devil in the detail - some thoughts about the next model of the basal ganglia. , 2009, Parkinsonism & related disorders.
[60] A. Lawrence,et al. The promiscuous mGlu5 receptor--a range of partners for therapeutic possibilities? , 2009, Trends in pharmacological sciences.
[61] P Jeffrey Conn,et al. Glutamate receptors as therapeutic targets for Parkinson's disease. , 2009, CNS & neurological disorders drug targets.
[62] E. Buerger,et al. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole , 2009, Current medical research and opinion.
[63] Qin Li,et al. Striatal Overexpression of ΔJunD Resets L-DOPA-Induced Dyskinesia in a Primate Model of Parkinson Disease , 2009, Biological Psychiatry.
[64] L. Grégoire,et al. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. , 2009, Parkinsonism & related disorders.
[65] J. Nutt,et al. Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism , 2008, Movement disorders : official journal of the Movement Disorder Society.
[66] M. Amalric,et al. Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats , 2008, Neuropharmacology.
[67] L. Grégoire,et al. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys , 2008, Neurobiology of Aging.
[68] P. Lewitt,et al. Protection against Parkinson’s disease progression: Clinical experience , 2008, Neurotherapeutics.
[69] L. Savegnago,et al. Neuroprotective effect caused by MPEP, an antagonist of metabotropic glutamate receptor mGluR5, on seizures induced by pilocarpine in 21-day-old rats , 2008, Brain Research.
[70] G. Nappi,et al. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease , 2008, Neurobiology of Disease.
[71] M. Croucher,et al. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6‐hydroxydopamine toxicity in vivo , 2007, Journal of neurochemistry.
[72] B. Moghaddam,et al. Positive Allosteric Modulation of Metabotropic Glutamate 5 (mGlu5) Receptors Reverses N-Methyl-D-Aspartate Antagonist-Induced Alteration of Neuronal Firing in Prefrontal Cortex , 2007, Biological Psychiatry.
[73] C. Konradi,et al. Spatiotemporal Pattern of Striatal ERK1/2 Phosphorylation in a Rat Model of L-DOPA–Induced Dyskinesia and the Role of Dopamine D1 Receptors , 2007, Biological Psychiatry.
[74] C. Goetz,et al. Levodopa‐induced dyskinesias , 2007, Movement disorders : official journal of the Movement Disorder Society.
[75] Qin Li,et al. Altered D1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates , 2007, Neurobiology of Disease.
[76] H. Shiono,et al. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions , 2006, Brain Research.
[77] A. Verkhratsky,et al. Changes in mGlu5 receptor expression in the basal ganglia of reserpinised rats. , 2006, European journal of pharmacology.
[78] P. Bramanti,et al. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease , 2006, Neurobiology of Disease.
[79] D. Grandy,et al. Interactions between Metabotropic Glutamate 5 and Adenosine A2A Receptors in Normal and Parkinsonian Mice , 2005, The Journal of Neuroscience.
[80] Jens-Uwe Peters,et al. Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity , 2005, Journal of Pharmacology and Experimental Therapeutics.
[81] Andrzej Pilc,et al. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats , 2005, Neuropharmacology.
[82] G. Fisone,et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia , 2005, Experimental Neurology.
[83] M. Amalric,et al. Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson’s disease , 2005, Psychopharmacology.
[84] K. Fuxe,et al. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP , 2005, Brain Research.
[85] B. Moghaddam,et al. Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release , 2004, Neuropsychopharmacology.
[86] P. Popoli,et al. Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid‐induced striatal toxicity: involvement of pre‐ and post‐synaptic mechanisms and lack of direct NMDA blocking activity , 2004, Journal of neurochemistry.
[87] M. Amalric,et al. Simultaneous Blockade of Adenosine A2A and Metabotropic Glutamate mGlu5 Receptors Increase their Efficacy in Reversing Parkinsonian Deficits in Rats , 2004, Neuropsychopharmacology.
[88] J. Nutt,et al. Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study) , 2004, Clinical neuropharmacology.
[89] Giuseppe Battaglia,et al. Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice , 2004, The Journal of Neuroscience.
[90] M. Amalric,et al. Metabotropic Glutamate 5 Receptor Blockade Alleviates Akinesia by Normalizing Activity of Selective Basal-Ganglia Structures in Parkinsonian Rats , 2003, The Journal of Neuroscience.
[91] A. Dilella,et al. Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse , 2003, The Journal of Neuroscience.
[92] N. Cosford,et al. [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. , 2003, Bioorganic & medicinal chemistry letters.
[93] J. Kemp,et al. Identification and characterization of a novel splice variant of the metabotropic glutamate receptor 5 gene in human hippocampus and cerebellum. , 2002, Brain research. Molecular brain research.
[94] M. Amalric,et al. Chronic But Not Acute Treatment with a Metabotropic Glutamate 5 Receptor Antagonist Reverses the Akinetic Deficits in a Rat Model of Parkinsonism , 2002, The Journal of Neuroscience.
[95] C. Romano,et al. Developmental regulation of metabotropic glutamate receptor 5b protein in rodent brain , 2002, Neuroscience.
[96] F. Nicoletti,et al. Selective Blockade of mGlu5 Metabotropic Glutamate Receptors Is Protective against Methamphetamine Neurotoxicity , 2002, The Journal of Neuroscience.
[97] E. Nestler,et al. Elevated levels of ΔFosB and RGS9 in striatum in Parkinson’s disease , 2001, Biological Psychiatry.
[98] G Bernardi,et al. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons , 2001, Neuroscience.
[99] G. Nappi,et al. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease , 2001, Annals of neurology.
[100] G. Battaglia,et al. Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective , 2000, Neuropharmacology.
[101] D. Jane,et al. Metabotropic glutamate autoreceptors of the mGlu5 subtype positively modulate neuronal glutamate release in the rat forebrain in vitro , 2000, Neuropharmacology.
[102] L. Seeberger,et al. A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia , 2000, Clinical neuropharmacology.
[103] M. Andersson,et al. Striatal fosB Expression Is Causally Linked with l -DOPA-Induced Abnormal Involuntary Movements and the Associated Upregulation of Striatal Prodynorphin mRNA in a Rat Model of Parkinson's Disease , 1999, Neurobiology of Disease.
[104] M. Andersson,et al. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-DOPA treatment , 1999, Neuroscience.
[105] C. Parsons,et al. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studies , 1997, Neuroscience & Biobehavioral Reviews.
[106] L. Grégoire,et al. Risk Factors for Peak Dose Dyskinesia in 100 Levodopa-treated Parkinsonian Patients , 1996, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[107] A. N. van den Pol,et al. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain , 1995, The Journal of comparative neurology.
[108] J. Kebabian,et al. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys. , 1993, The Journal of pharmacology and experimental therapeutics.
[109] J. Penney,et al. The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.
[110] P. Calabresi,et al. Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson's disease. , 2010, Progress in brain research.
[111] T. Chase,et al. Striatal glutamatergic mechanisms and extrapyramidal movement disorders , 2009, Neurotoxicity Research.
[112] Qin Li,et al. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. , 2007, Neurobiology of disease.
[113] E. Nestler,et al. Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. , 2001, Biological psychiatry.